Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registry-Reference-Cited by-同舟云学术

Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registry

Published:2017-10-09 Issue:4 Volume:44 Page:466-474
ISSN:0929-5305
Container-title:Journal of Thrombosis and Thrombolysis
language:en
Short-container-title:J Thromb Thrombolysis

Author:

Rasia Marta,Solinas Emilia,Marino Massimiliano,Guastaroba Paolo,Menozzi Alberto,Cattabiani Maria Alberta,Tadonio Iacopo,De Palma Rossana,Vignali Luigi

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Hematology

Link

http://link.springer.com/article/10.1007/s11239-017-1567-0/fulltext.html

Reference33 articles.

1. Mehta SR, Yusuf S (2000 Dec) Clopidogrel in unstable angina to prevent recurrent events (CURE) study investigators. The Clopidogrel in unstable angina to prevent recurrent events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 21(24):2033–2041

2. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L (2009) Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with Clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J 157(4):599–605. doi: 10.1016/j-ahj.2009.01.003

3. Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, Goodrich E, Mauri L, Ophuis TO, Ruda M, Spinar J, Seung KB, Hu D, Dalby AJ, Jensen E, Held P, Morrow DA, Braunwald E, Sabatine MS (2016 Sep) Prevention of stroke with ticagrelor in patients with prior Myocardial infarction: insights from PEGASUS-TIMI 54 (prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54). Circulation 20(12):86171. doi: 10.1161/CIRCULATIONAHA.116.024637

4. Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA (2012) American College of Cardiology/American Heart Association/European Society of cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (trial to assess improvement in therapeutic outcomes by optimiziong platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Circulation 125(4):577–583. doi: 10.1161/CIRCULATION.111.041160

5. Steg G, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van’t Hof A, Widimsky P, Zahger D (2012) Committee for practise guidelines ESC. (CPG) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of CARDIOLOGY (ESC). Eur Heart J 33:2569–2619

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention;Heart;2021-03-12

3. Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis;American Journal of Cardiovascular Drugs;2019-03-04

4. Chronic Kidney Disease and Third-Generation P2Y12 Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year;The Journal of Clinical Pharmacology;2018-09-12